MeSH tree: D13.570.583.138.806
One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors—ticagrelor or prasugrel—in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the same level of benefit ...
Nov 10, 2025
0
14
Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction and cardiogenic ...
Sep 1, 2025
0
19
Dual antiplatelet therapy after cardiac bypass surgery is no more effective than acetylsalicylic acid alone and also increases the risk of serious bleeding. This is shown in a study by researchers at Karolinska Institutet ...
Sep 1, 2025
0
20
There was no benefit to modulating the intensity of antiplatelet therapy compared with standard antiplatelet therapy in high-risk patients who had undergone complex stenting procedures, according to late-breaking research ...
Sep 1, 2025
0
10
In a follow-up investigation into the multibillion-dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval.
Jun 19, 2025
0
88
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major bleeding, according to a study ...
Mar 31, 2025
0
10
For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower bleeding risk, without ...
Feb 19, 2025
0
11
An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the US and Brilique in Europe), ...
Dec 12, 2024
0
26
Treatment with ticagrelor alone results in a lower rate of clinically relevant bleeding compared with ticagrelor and aspirin among patients with an acute coronary syndrome who had percutaneous coronary intervention and remained ...
Apr 13, 2024
0
66
Withdrawing aspirin one month after percutaneous coronary intervention (PCI) in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared ...
Apr 7, 2024
0
77
